1. Medtech Insight
  2. >>Geography
  3. >>Asia

TriReme Strategy Bridges Pacific For Medical Device Start-Ups

The road to the rising markets of Asia can be daunting to some medical device start-ups, but not Pleasanton, CA-based TriReme Medical Inc. For the past two years, the privately held maker of balloon-equipped catheters has constructed inroads to Asia through the city-state of Singapore. Two years ago, the company established a subsidiary in Singapore, enabling it to dip into the Asia-based capital pool.

The road to the rising markets of Asia can be daunting to some medical device start-ups, but not Pleasanton, CA-based TriReme Medical Inc. For the past two years, the privately held maker of balloon-equipped catheters has constructed inroads to Asia through the city-state of Singapore. Two years ago, the company established a subsidiary in Singapore, enabling it to dip into the Asia-based capital pool. That same year, TriReme also played the role of investor, contributing to a Series A round raised by Quattro Vascular Pte. Ltd., developer of an innovative balloon-based catheter.

Today, those investments are paying dividends. TriReme has opened research and development, manufacturing and sales offices in Singapore. The operations center will serve as a base for TriReme’s broader reach...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Asia

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Medical Devices Not The Focus Of FDA’s Plans To Step Up Foreign Inspections, Expert Says

 
• By Brian Bossetta

The US FDA recently announced plans to carry out more unannounced inspections of foreign facilities. But those inspections will primarily target drug producers, with less attention and resources allocated to those making devices.

Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

 
• By Marion Webb

Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

Don’t Sleep On Inspections: Experts Warn FDA Maintains Enforcement Resources

 
• By Brian Bossetta

Manufacturers of medical products would be foolish to think that recent upheavals at the US FDA will result in a lack of inspections in the coming years. A panel of experts discussed the current state of inspections during a webinar hosted by the Food and Drug Law Institute.

More from Geography

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.